World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
20879
World Ranking
17232
National Ranking
8635

David R. Spriggs publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where David R. Spriggs sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 371 publications — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

David R. Spriggs D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where David R. Spriggs sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

David R. Spriggs is affiliated with Massachusetts General Hospital in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology. A significant portion of their work focuses on subfields such as Molecular Biology, Oncology, Immunology, Radiology, Nuclear Medicine and Imaging, and Obstetrics and Gynecology.

The scientist's research topics include:

  • Monoclonal and Polyclonal Antibodies Research
  • Ovarian Cancer Diagnosis and Treatment
  • Glycosylation and Glycoproteins Research
  • Endometrial and Cervical Cancer Treatments
  • CAR-T Cell Therapy Research
  • Galectins and Cancer Biology
  • Cancer Immunotherapy and Biomarkers

Prominent publication venues where David R. Spriggs frequently publishes include:

  • Cancer Research
  • Gynecologic Oncology
  • Journal of Ovarian Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research

The recent papers by David R. Spriggs cover topics in oncology and immunotherapy with some of the titles and years as follows:

  • Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer, 2022, JAMA Oncology
  • Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition, 2021, Frontiers in Immunology
  • Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies, 2021, Scientific Reports
  • Galectins and Ovarian Cancer, 2020, Cancers
  • A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma, 2020, Journal of Translational Medicine

David R. Spriggs collaborates frequently with other researchers. Notable co-authors include:

  • Oladapo Yeku
  • Bo R. Rueda
  • Cesar M. Castro
  • Raj Kumar
  • Eric Eisenhauer

Best Publications

  • Detection of circulating tumor necrosis factor after endotoxin administration.

    Hamish R. Michie;Kirk R. Manogue;David R. Spriggs;Arthur Revhaug

  • Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial

    Martee L. Hensley;Robert Maki;E. Venkatraman;Gennifer Geller

  • A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

    Carol Aghajanian;Steven Soignet;Don S. Dizon;Christine S. Pien

  • Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation

    Dennis E. Hallahan;David R. Spriggs;Michael A. Beckett;Donald W. Kufe

  • Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings.

    H R Michie;D R Spriggs;K R Manogue;M L Sherman

  • Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

    David R. Spriggs;Matthew L. Sherman;Hamish Michie;Kristina A. Arthur

  • IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo

    Mythili Koneru;Terence J. Purdon;David Spriggs;Susmith Koneru

  • Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha

    Dominik B. Dubravec;David R. Spriggs;John A. Mannick;Mary L. Rodrick

  • Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

    Oladapo O. Yeku;Terence J. Purdon;Mythili Koneru;David Spriggs

  • BRCA1 Up-Regulation Is Associated with Repair-mediated Resistance to cis-Diamminedichloroplatinum(II)

    Amreen Husain;Guoshun He;Ennapadam S. Venkatraman;David R. Spriggs

  • Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

    Paul Sabbatini;Takemasa Tsuji;Luis Ferran;Erika Ritter

  • Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.

    D Fennelly;C Aghajanian;F Shapiro;C O'Flaherty

  • A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16 ecto directed chimeric antigen receptors for recurrent ovarian cancer

    Mythili Koneru;Mythili Koneru;Roisin O’Cearbhaill;Roisin O’Cearbhaill;Swati Pendharkar;David R Spriggs;David R Spriggs

  • Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.

    M L Sherman;D R Spriggs;K A Arthur;K Imamura

  • Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

    Xingxing Zang;Peggy S Sullivan;Robert A Soslow;Rebecca Waitz

  • Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

    A. Craig Lockhart;Mace L. Rothenberg;Jakob Dupont;Wendy Cooper

  • Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.

    Robert A Soslow;Guangming Han;Kay J Park;Karuna Garg

  • Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma : Results of a prospective study

    Martee L. Hensley;Nicole Ishill;Robert Soslow;Joseph Larkin

  • BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

    Rachel N. Grisham;Gopa Iyer;Karuna Garg;Deborah DeLair

  • Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

    H H Bailey;R T Mulcahy;K D Tutsch;R Z Arzoomanian

Frequent Co-Authors

Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center
Donald Kufe
Donald Kufe Harvard University
George Wilding
George Wilding University of Wisconsin–Madison
Renier J. Brentjens
Renier J. Brentjens Roswell Park Cancer Institute
Joan H. Schiller
Joan H. Schiller University of Virginia
Leonard Saltz
Leonard Saltz Memorial Sloan Kettering Cancer Center
Gary K. Schwartz
Gary K. Schwartz Memorial Sloan Kettering Cancer Center
Jason A. Koutcher
Jason A. Koutcher Memorial Sloan Kettering Cancer Center
Charles A. Dinarello
Charles A. Dinarello University of Colorado Anschutz Medical Campus
Nancy E. Kemeny
Nancy E. Kemeny Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring alternative healthcare careers or flexible study options, there are many related online degrees to consider. Medical support roles are in high demand, and starting with medical coding and billing classes online with financial aid is an accessible way to enter the medical field without committing to a long degree.

For those interested in nursing, finding nursing schools that don't require teas test can simplify the admissions process and help you start your career sooner. If you already have a background in nursing, pursuing adn to msn bridge programs provides a streamlined path to advanced practice roles and leadership positions in healthcare.

Additionally, an online healthcare administration degree is ideal if you’re more interested in the management and policy aspects of the medical industry, opening doors to leadership jobs in hospitals and clinics. These related degrees offer flexible, practical alternatives for building a rewarding career in healthcare.

Best Scientists Citing David R. Spriggs

Trending Scientists

Recently Published Articles